Session 6: Insights from Health Care Systems on Bispecifics: Patient Treatment, Monitoring and Transition of Care : Episode 12
Key Takeaways from Health Care Systems on the Role of Bispecifics in MM
The panel closes their discussion by highlighting crucial takeaways about the use of bispecific antibodies in the treatment of multiple myeloma.
EP: 1.Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)
EP: 2.Data Updates on BCMA-Targeting Bispecific Antibodies in R/R MM Treatment
EP: 3.MonumenTAL-1: Evaluating the Anti- GPRC5D-Targetings Bispecific in R/R MM
EP: 4.FCRH5-Targeting and Other Emerging Bispecifics in R/R MM
EP: 5.Incorporating Teclistamab in R/R MM: Insights from Clinical Practices Across the US
EP: 6.Step-up Dosing and Monitoring in Patients with MM on Bispecifics: Health System Perspectives
EP: 7.Best Practices for Transition of Care in Patients with MM on Teclistamab
EP: 8.Managing Infections and Other Toxicities Associated with Bispecifics in MM
EP: 9.Sequencing BCMA-Targeting Bispecifics in R/R MM Treatment
EP: 10.Choosing Between BCMA and Non-BCMA Bispecifics in Multiple Myeloma Treatment
EP: 11.Future Perspectives on the Role of Bispecifics in MM
Now Viewing
EP: 12.Key Takeaways from Health Care Systems on the Role of Bispecifics in MM
EP: 13.Teclistamab Reviewed as Potential Treatment Option in Relapsed/Refractory Multiple Myeloma
EP: 14.Treatment Recommendations for Relapsed Multiple Myeloma
Recent Videos
Related Content
